Course description
There is a paucity of treatments for many psychiatric disorders. Classical psychedelic drugs stimulate the serotonin 2A receptor (5-HT2AR) and have shown a good safety profile. Some of these compounds have shown rapid and sustained therapeutic effects in some human clinical trials and they are currently being explored in several clinical trials for various psychiatric and neurological disorders. However, it is still unclear how the molecular and functional mechanisms of the substances relate to these subjective and clinical effects, and how treatments should be designed to optimize cost-effective and lasting effects. The overall aim of this course is to provide an overview of the research front in the field of classical psychedelics - from preclinical studies to clinical practice.
Requirements and Selection
Prerequisite courses, or equivalent
No prerequisite courses, or equivalent, demanded for this course.
Selection
Selection will be based on:
1) The relevance of the course syllabus for the applicant’s doctoral project (according to written motivation).
2) Start date of doctoral studies (priority given to earlier start date).
Course director
Johan Lundberg
Maria Beckman
Course syllabus
K8F6025
Department
Department of Clinical Neuroscience
Doctoral programme
Neuroscience
Type of course
**Other course
Keywords
Psychedelic Science, Preclinical Studies , Prekliniska Studier , Clinical Practice, Klinisk Praktik, Psykedelisk Vetenskap